Research & Development

Research & DevelopmentR&D Pipeline

       

Peripheral Arterial Disease Therapy using Angiogenesis in PLX-PAD cells

 

Peripheral Arterial Disease (PAD)


    Symptom vary from muscle pain when walking or using affected muscles
     (Intermittent Claudication, IC) to rest pain (Critical Limb Ischemia, CLI)
    Leading to chronic severe reduction in quality of life
    If untreated, tissue necrosis caused by lack of blood flow in blocked
     blood vessel
    Narrowed and blocked blood vessel mainly due to hardening of arteries

 

Limitation of Current Treatment


    No regeneration in damaged blood vessels caused by lack of blood flow

 

CHA Biotech’s PLX-PAD


    Placenta-derived cell therapy product which has functions of secreting EGF
     (Epidermal Growth Factor) and VEGF (Vascular Endothelial Growth Factor)
    Korean market exclusivity acquired via strategic partnership with Pluristem
     Therapeutics in Israel (2013)


    

 

Cerebral Infarction Therapy using eCASs Program



Stroke


    Disease causing brain necrosis due to disturbance in blood vessel
      supplying blood to brain
    Associated with high mortality rate or survival with severe neurological
      deficits

             

CHA Biotech’s CB-AC-01


    Mesenchymal stem cell therapy derived from umbilical cord tissue
    Stored frozen and injectable immediately since no cultivation period require
    Co-development with CHA University and Bundang CHA Medical Center
   


   

Demonstrated robust safety profile for ‘Cordstem-ST’ via systemic administration Signals of efficacy seen
with statistical significance at week 24 during review time period

 

 

Alzheimer’s Disease Therapy using ePACs Program



Alzheimer’s Disease (AD)


    No definitive cause and mechanism of AD found
    Associated with severe memory problems and other intellectual disabilities
     to varying degrees, ultimately leading to death


              


Limitation of Current Treatment


    No definite results identified to prevent or delay onset of AD
      from 2 FDA-approved drugs

CHA Biotech’s CB-AC-02


    Mesenchymal stem cell therapy derived from umbilical tissue
    Stored frozen and injectable immediately since no cultivation period required
    Co-development with CHA University and Bundang CHA Medical Center


   
 
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Businesses
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
Corporate Filings
Stock Information
IR Presentations